Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:TROV

Cardiff Oncology (TROV) Stock Price, News & Analysis

Cardiff Oncology logo

About Cardiff Oncology Stock (NASDAQ:TROV)

Key Stats

Today's Range
$3.12
$3.36
50-Day Range
$1.19
$24.71
52-Week Range
$0.70
$3.46
Volume
683,914 shs
Average Volume
648,892 shs
Market Capitalization
$35.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.

Receive TROV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardiff Oncology and its competitors with MarketBeat's FREE daily newsletter.

TROV Stock News Headlines

Cardiff Oncology publishes onvansertib combination data in journal
625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
Craig-Hallum Sticks to Its Buy Rating for Cardiff Oncology (CRDF)
See More Headlines

TROV Stock Analysis - Frequently Asked Questions

Cardiff Oncology, Inc. (NASDAQ:TROV) issued its earnings results on Thursday, February, 27th. The medical research company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.65) by $0.14. The medical research company had revenue of $0.09 million for the quarter. Cardiff Oncology had a negative trailing twelve-month return on equity of 202.00% and a negative net margin of 3,688.31%.

Cardiff Oncology shares reverse split before market open on Wednesday, February 20th 2019. The 1-6 reverse split was announced on Tuesday, February 19th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 19th 2019. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cardiff Oncology investors own include XOMA (XOMA), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Bristol-Myers Squibb (BMY), OPKO Health (OPK), Alnylam Pharmaceuticals (ALNY) and VBI Vaccines (VBIV).

Company Calendar

Last Earnings
2/27/2020
Today
11/02/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:TROV
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-16,410,000.00
Net Margins
-3,688.31%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$250,000.00
Book Value
$0.94 per share

Miscellaneous

Free Float
N/A
Market Cap
$35.29 million
Optionable
Not Optionable
Beta
1.04
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (NASDAQ:TROV) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners